2026年,尽管在强劲的现金流动和新产品计划的支持下出现了专利损失,但辉瑞的股息在2026年依然稳定。 Pfizer's dividend remains secure in 2026 despite patent losses, backed by strong cash flow and new product plans.

随着2026年的开始,辉瑞的股息尽管面临挑战,但在强劲的自由现金流动和持续增长的历史的支持下似乎保持稳定。 As 2026 begins, Pfizer’s dividend appears stable despite challenges, supported by strong free cash flow and a history of consistent increases. 虽然其收入支付比率高达99.4%,但93.3%的自由现金流量比率更可持续。 While its earnings payout ratio is high at 99.4%, the 93.3% free cash flow ratio is more sustainable. 该公司面临Eliquis和Xeljanz等关键药物专利到期带来的收入压力,但领导层重申对红利的承诺,并计划通过新产品投资抵消损失。 The company faces revenue pressures from patent expirations on key drugs like Eliquis and Xeljanz, but leadership reaffirms commitment to dividends and plans to offset losses through new product investments.